PMC:7195088 / 31841-32042 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T26","span":{"begin":185,"end":190},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T164","span":{"begin":68,"end":76},"obj":"Disease"}],"attributes":[{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T178","span":{"begin":167,"end":170},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T430","span":{"begin":14,"end":25},"obj":"Chemical"}],"attributes":[{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28."}

{"project":"LitCovid-sentences","denotations":[{"id":"T252","span":{"begin":78,"end":129},"obj":"Sentence"},{"id":"T253","span":{"begin":130,"end":201},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28."}